Key result
In neonatal rat ventricular cardiomyocytes, HDL and its constituent sphingosine-1-phosphate (S1P) induce Stat3 activation via the S1P2 receptor, requiring ERK1/2 and Src stimulation.
Why the study?
Does the addition of S1P to reconstituted HDL improve Stat3 activation in neonatal rat ventricular cardiomyocytes?
Does the addition of S1P to reconstituted HDL improve Stat3 activation in neonatal rat ventricular cardiomyocytes?
Addition of S1P to reconstituted HDL enhances its capacity to activate the cardioprotective transcription factor Stat3 in ventricular cardiomyocytes via the S1P2 receptor and ERK1/2 pathway.
May warrant exploration of S1P-enriched HDL for cardioprotection; leaves open translation from rat cardiomyocytes to clinical use.
AIMS: High-density lipoprotein (HDL) has been reported to have cardioprotective properties independent from its cholesterol transport activity. The influence of native HDL and reconstituted HDL (rHDL) on Stat3, the transcription factor playing an important role in myocardium adaptation to stress, was analysed in neonatal rat ventricular cardiomyocytes. We have investigated modulating the composition of rHDL as a means of expanding its function and potential cardioprotective effects. METHODS AND RESULTS: Stat3 phosphorylation and activation were determined by western blotting and electrophoretic mobility shift assay (EMSA). In ventricular cardiomyocytes, HDL and the HDL constituent sphingosine-1-phosphate (S1P) induce a concentration- and time-dependent increase in Stat3 activation. They also enhance extracellular signal-regulated kinases (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) phosphorylation. U0126, a specific inhibitor of MEK1/2, the upstream activator of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580 has no significant effect. Inhibition of the tyrosine kinase family Src (Src) caused a significant reduction of Stat3 activation, whereas inhibition of phosphatidylinositol 3-kinase (PI3K) had no effect. S1P and rHDL containing S1P have a similar strong stimulatory action on Stat3, ERK1/2, and p38 MAPK comparable to native HDL. S1P-free rHDL has a much weaker effect. Experiments with agonists and antagonists of the S1P receptor subtypes indicate that HDL and S1P activate Stat3 mainly through the S1P2 receptor. CONCLUSION: In ventricular cardiomyocytes, addition of S1P to rHDL enhances its therapeutic potential by improving its capacity to activate Stat3. Activation of Stat3 occurs mainly via the S1P constituent and the lipid receptor S1P2 requiring stimulation of ERK1/2 and Src but not p38 MAPK or PI3K. The study underlines the therapeutic potential of tailoring rHDL to confront particular clinical situations.
No takes yet. Share an insight, caveat, or question.
Frias et al. (2009) studied Neonatal rat ventricular cardiomyocytes. Native HDL, reconstituted HDL (rHDL), and sphingosine-1-phosphate (S1P) was evaluated on Stat3 phosphorylation and activation. In neonatal rat ventricular cardiomyocytes, HDL and its constituent sphingosine-1-phosphate (S1P) induce Stat3 activation via the S1P2 receptor, requiring ERK1/2 and Src stimulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: